Table 2.
Drug | 3 Cpro | Mpro |
---|---|---|
alpha-ketoamide (11a) [50] | 6.56 ± 3.10 (CVB3) | 1.95 ± 0.24 |
alpha-ketoamide (11 r) [50] | 0.95 ± 0.15 (CVB3) | 0.71 ± 0.36 |
alpha-ketoamide (11 u) [50] | 1.93 ± 0.43 (CVB3) | 1.27 ± 0.34 |
PF-00835231 [51] | 1.70 ± 1.00 (HRV) | 0.004 ± 0.0003 |
43,146 [52] | 5.40 ±- 0.20 (CVB3) | 8.10 ± 0.90 |
PSI [54] | 13.74 ± 3.86 (EV-A71) | 10.38 ± 2.90* |
GC-376 [54] | 0.14 ± 0.03 (EV-A71) | 0.03 ± 0.01* |
Calpain inhibitor II [54] | >20 (EV-A71) | 0.97 ± 0.27* |
Calpain inhibitor XII [54] | >20 (EV-A71) | 0.45 ± 0.06* |
MAC-5576 [53] | 0.54 ± 0.09 (HAV) | 0.50 ± 0,.0 |
MAC-22,272 [53] | 0.90 ± 0.10 (HAV) | 2.60 ± 0,.0 |
IC50 valuesIC50 values
IC50 values (µM) of drugs tested against marked enterovirus 3 Cpro and SARS-CoV-1 Mpro. *Tested against SARS-CoV-2